An arm rehabilitation system for exercising a user's arm. The system provides an arm support device moveable upon a support surface by a user's first arm. The arm support device has a main body configured to movably engage the support surface on one side and has a hand support portion on an opposing side at or toward one end of the body for supporting a user's hand of the first arm. A primary hand support formation protrudes from the hand support portion and a secondary hand support handle extends from the main body at or toward the periphery of the hand support portion. An adjustable switch support boom assembly is also mounted to the main body and has at least one operable user input component for generating an actuation signal in response to operation by the user. An onboard motion tracking system mounted to or within the main body is configured to sense motion of the main body to enable user interaction with an interactive computer system running an application program.
A63B 23/12 - Exercising apparatus specially adapted for particular parts of the body for limbs, i.e. upper or lower limbs, e.g. simultaneously for upper limbs
The present invention relates to methods and peptides for the modulation of gap junction communication between cells. In particular the present invention relates to methods for modulating gap junction communication in mammalian cells, comprising treating the cells with an effective amount of a peptide having the amino acid sequence FHPSS (SEQ ID NO: 3), or a variant form thereof having at least 60% sequence identity with the amino acid sequence and being at least 4 amino acids in length.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventor
Clinch, Keith
Crump, Douglas Ronald
Evans, Gary Brian
Hazleton, Keith Zachary
Mason, Jennifer Mary
Schramm, Vern L.
Tyler, Peter Charles
Abstract
The invention relates to compounds of formula (I) that are inhibitors of hypoxanthine and/or guanine purine phosphoribosyltransferases and to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit hypoxanthine and/or guanine purine phosphoribosyltransferases. Such diseases include malaria.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
INDUSTRIAL RESEARCH LIMITED (New Zealand)
Inventor
Schramm, Vern, L.
Clinch, Keith
Tyler, Peter, Charles
Evans, Gary, Brian
Furneaux, Richard, Hubert
Abstract
The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5'- methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A method for real-time RL and/or ROSL dose rate measuring in an environment exposed to a radiation source(s). The method comprises the steps of exposing a dosimeter to the environment for irradiation by the radiation source(s), the dosimeter comprising a phosphor-doped fluoroperovskite compound, sensing the RL or ROSL emitted light from the dosimeter during irradiation by the radiation source(s) and generating a representative light detection signal, and recording or generating a real-time measure of dose rate in the environment based on the light detection signal. A radiation dosimeter detection system comprising a phosphor-doped fluoroperovskite compound, the dosimeter coupled to a detector by an optical fibre. The detector comprises first and second optical stimulation sources that transmit light over the optical fibre to the dosimeter in first and second wavelength ranges. An optical detector senses light emitted from the dosimeter from which read-out dose information is generated.
A surround sound system for reproducing a spatial sound field in a sound control region within a room having at least one sound reflective surface. The system uses multiple steerable loudspeakers located about the sound control region, each loudspeaker having a plurality of different individual directional response channels being controlled by respective speaker input signals to generate sound waves emanating from the loudspeaker with a desired overall directional response. A control unit connected drives each of the loudspeakers and has pre-configured filters based on measured acoustic transfer functions for the room for filtering the input spatial audio signals to generate the speaker input signals for all the loudspeakers to generate sound waves with co¬ ordinated overall directional responses that combine together at the sound control region in the form of either direct sound or reflected sound from the reflective surface(s) of the room to reproduce the spatial sound field.
H04S 3/02 - Systems employing more than two channels, e.g. quadraphonic of the matrix type, i.e. in which input signals are combined algebraically, e.g. after having been phase shifted with respect to each other
G10L 19/00 - Speech or audio signal analysis-synthesis techniques for redundancy reduction, e.g. in vocodersCoding or decoding of speech or audio signals, using source filter models or psychoacoustic analysis
H04R 5/02 - Spatial or constructional arrangements of loudspeakers
The invention relates to a process for the aminohydroxylation of alkenes using N-oxycarbamate reagents, e.g. N-acyloxycarbamate, N-alkyloxycarbonyloxycarbamate and N-aralkoxycarbonyloxycarbamate reagents. The invention particularly relates to an intermolecular aminohydroxylation reaction that can be carried out in the absence of added base. The invention also relates to novel N-oxycarbamate reagents that are stable crystalline materials. The process of the invention is useful in the synthesis of compounds having a vicinal amino alcohol moiety, such as biologically active compounds.
C07C 227/20 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino acids or derivatives thereof, e.g. hydrolysis of carbamates
C07D 207/18 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
C07D 207/02 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
The invention relates to an exercise system/device for exercising a user's upper limb. The exercise system/device is intended for use in rehabilitating patients suffering hemiparesis that causes one upper limb to be at least partially paralysed. For example, the exercise system/device can be used for neuroplastic retraining rehabilitation techniques for enabling patients to regain control of their paralysed upper extremities, including shoulders, elbows, wrists and fingers, but primarily their shoulders and elbows via larger arm movements. This is achieved through the use of an elongate handle and a motion sensing device associated with the handle for communicating the user's movements of the handle to a gaming system. Although the exercise system/device is primarily for rehabilitation of patients suffering hemiparesis, it will be appreciated that it may also be used by any person for bilateral training and exercising upper limbs.
G06F 3/033 - Pointing devices displaced or positioned by the userAccessories therefor
A63F 13/06 - using player-operated means for controlling the position of a specific area on the display
A63B 23/16 - Exercising apparatus specially adapted for particular parts of the body for limbs, i.e. upper or lower limbs, e.g. simultaneously for upper limbs for hands or fingers
9.
3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY (USA)
INDUSTRIAL RESEARCH LIMITED (New Zealand)
Inventor
Evans, Gary Brian
Longshaw, Alistair Ian
Schramm, Vern L.
Tyler, Peter, Charles
Abstract
The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
A handheld measurement device (10) for enabling a user to measure a person's muscle strength and range of motion associated with a limb movement about a joint in a movement plane. The device comprises a contact surface (28) that is arranged to contact a part of the person's limb, a 3D orientation sensor that is arranged to sense the 3D orientation of the device in 3D space and generate representative 3D orientation signals during the limb movement, and a force sensor that is arranged to sense the force applied by the person's limb to the contact surface and generate representative force signals. A control system receives the 3D orientation and force signals and processes those signals to generate force data and angular rotation data.
An arm exercise system (10) comprising an arm trolley (14) having one or more support wheels and which is arranged to support a user's arm for movement over a surface via the wheel(s). The arm trolley (14) also has an actuator(s) associated with one or more of the wheel(s) and which are operable to apply a level of braking to resist movement of the wheel(s). The system (10) further comprises a motion tracking system (16) that is arranged to sense and track movement of the trolley (14) over the surface and generate representative position data relating to the movement of the trolley. A computer system (18) is arranged to receive the representative position data to enable a user (12) to interact with a program running on the computer system via movement of the arm trolley (14) over the surface.
A63B 23/12 - Exercising apparatus specially adapted for particular parts of the body for limbs, i.e. upper or lower limbs, e.g. simultaneously for upper limbs
A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
A bilateral upper limb exercise device (10) for exercising a user's arms comprising a central mounting structure (12) that is mountable to a fixed surface or structure (15), left and right limb supports (14a,14b) for supporting the forearm and/or hand of a respective arm of the user, and a pair of articulated linkage arms (22a,22b) that are pivotably coupled to opposite sides of the central mounting structure (12) and which are arranged to support a respective limb support (14a,14b) for movement in at least two degrees of freedom in a two-dimensional (2D) movement plane. A mirroring mechanism is also operatively coupled to the articulated linkage arms (22a,22b) such that movement of the opposing limb support relative to a central line of symmetry of the device.
A63B 23/12 - Exercising apparatus specially adapted for particular parts of the body for limbs, i.e. upper or lower limbs, e.g. simultaneously for upper limbs
A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
A swath beam acoustic transducer (100) for projecting and/or receiving acoustic swath beams (108). The transducer comprises an array of active acoustic elements (104) that are arranged to collectively provide an elongate concave radiation surface (106) with an associated acoustic aperture (110). The array of active acoustic elements (104) is operable to project and/or receive acoustic swath beams (108) via the radiation surface (106).
A process for the separation of carbon dioxide from gas mixtures is disclosed in which a metal oxide sorbent, which is used to capture and release carbon dioxide, is recycled. The process incorporates the regeneration of the carbon dioxide capture capacity of the metal oxide to maintain a high capture capacity over many cycles. The regeneration involves hydrating the metal oxide and then heating the resulting metal hydroxide under a gas atmosphere that is effective to suppress the dehydration of the hydroxide so that dehydration occurs at an elevated temperature. The regeneration may also be used independently from the carbon dioxide separation process to produce, from a metal hydroxide, a metal oxide having an enhanced resistance to attrition and fragmentation.
B01J 8/18 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with fluidised particles
B01D 53/96 - Regeneration, reactivation or recycling of reactants
B01J 20/04 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
The invention relates to a process for preparing compounds that are inhibitors of nucleoside phosphorylases and nucleosidases, in particular, compounds that have a methylene link between a nucleoside base analogue moiety of the molecule and a sugar analogue moiety, via an amino nitrogen of the sugar analogue moiety.
The invention relates to the use of angiogenic crystallin proteins to promote angiogenesis, wound healing and/or endothelial cell migration. Alpha A crystallin and βB2 crystallin have particular application in these methods. The crystallins will usually be in monomeric form. Typically, truncated form(s) of βB2 crystallin protein are utilized as can be prepared by partial hydrolysis of the protein by a protease enzyme such as elastase I. Methods for the purification of crystallin proteins from eye tissue are also described.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 1/16 - ExtractionSeparationPurification by chromatography
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A beam forming system (10) for acoustic or electromagnetic beams comprising one or more beam forming elements (2) that are arranged to provide a doubly ruled radiation surface.
H01Q 19/12 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using reflecting surfaces wherein the surfaces are concave
H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the relative phase or relative amplitude of energisation between two or more active radiating elementsArrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture
H01Q 15/16 - Reflecting surfacesEquivalent structures curved in two dimensions, e.g. paraboloidal
H04B 13/00 - Transmission systems characterised by the medium used for transmission, not provided for in groups
G01S 1/54 - Narrow-beam systems producing at a receiver a pulse-type envelope signal of the carrier wave of the beam, the timing of which is dependent upon the angle between the direction of the receiver from the beacon and a reference direction from the beaconOverlapping broad beam systems defining a narrow zone and producing at a receiver a pulse-type envelope signal of the carrier wave of the beam, the timing of which is dependent upon the angle between the direction of the receiver from the beacon and a reference direction from the beacon
18.
USE OF IONIC LIQUIDS FOR EXTRACTION OR FRACTIONATION OF LIPIDS
The invention relates to a process which employs an ionic liquid for extracting unsaturated lipophilic compounds from lipid containing feed materials. The process can be used for extracting polyunsaturated fatty acids, or their derivatives, from feed materials containing a mixture of fatty acids or their derivatives.
C07C 7/10 - Purification, separation or stabilisation of hydrocarbonsUse of additives by extraction, i.e. purification or separation of liquid hydrocarbons with the aid of liquids
C11B 13/00 - Recovery of fats, fatty oils or fatty acids from waste materials
An apparatus and method for measuring perfusion in a tissue. The method comprising the steps of recording images of the tissue under laser light, calculating a plurality of contrast images from the plurality of images of the tissue, determining a power spectrum of scattered light from the plurality of contrast images, and determining perfusion from the power spectrum. The apparatus comprises a digital video camera, a laser light source, and a processor arranged to operate the camera to produce a plurality of images with different exposure times, receive the plurality of images from the camera and process the images to determine a power spectrum and determine perfusion from the power spectrum.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventor
Evans, Gary Brian
Furneaux, Richard Hubert
Greatrex, Ben William
Schramm, Vern L.
Tyler, Peter Charles
Abstract
Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and X are each independently selected from hydrogen, CH2OH, CH2OQ and CH2SQ; Y and Z are each independently selected from hydrogen, halogen, CH2OH, CH2OQ, CH2SQ, SQ, OQ and Q; Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R1 is a radical of the formula (II) or R1 is a radical of the formula (III) A is selected from N, CH and CR2, where R2 is selected from halogen, alkyl, aralkyl, aryl, OH, NH2, NHR3, NR3R4 and SR5, where R3, R4 and R5 are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R2 is optionally substituted with hydroxy or halogen when R2 is alkyl, aralkyl or aryl; B is selected from hydroxy, NH2, NHR6, SH, hydrogen and halogen, where R6 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; D is selected from hydroxy, NH2, NHR7, hydrogen, halogen and SCH3, where R7 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; E is selected from N and CH; G is a C1-4 saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The invention relates to compounds which are immunomodulatory compounds and, in particular, can induce IL-12 secretion. The invention also relates to compositions containing the compounds, precursors, and prodrugs of these compounds, use of these compounds as adjuvants in combination with vaccines, and use of these compounds for treatment of diseases or conditions relating to infection, atopic disorders, or cancer.
A method of detecting interference in a received sample vector using hidden Markov modelling by first estimating noise variance, where estimating noice variance comprises the steps of receiving a sample vector of noise and interference, sorting the sample vector in the frequency domain by order of increasing magnitude to produce an ordered vector, finding a sub-vector of the ordered vector that minimises the distance from a noise measure, and estimating the noise variance.
NATIONAL INSTITUTE OF WATER AND ATMOSPHERIC RESEARCH LIMITED (New Zealand)
POWER PROJECTS LIMITED (New Zealand)
Inventor
Gardiner, Alister
Le-Ngoc, Lan
Caughley, Alan, James
Abstract
A wave energy converter (10) for extracting useful energy from wave motion. The converter (10) comprises an active float (12) that is arranged to float on the water, and being arranged to heave and surge in response to wave motion acting on the active float, and an elongate reactive body (14) that is arranged to be suspended in a substantially submerged state into the water and having sufficient surface area and length such that it pitches in response to wave motion- acting on the reactive body. The active float (12) and reactive body (14) are pivotably coupled for pivotable movement relative to each other about a single pivot axis (16) in response to heaving and surging of the active float and pitching of the reactive body. The converter also comprises a power output system that is driven by the pivotable movement about the pivot axis to capture the useful energy.
F03B 13/12 - Adaptations of machines or engines for special useCombinations of machines or engines with driving or driven apparatusPower stations or aggregates characterised by using wave or tide energy
24.
ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventor
Gulab, Shivali, Ashwin
Abstract
The present invention relates to compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventor
Clinch, Keith
Evans, Gary Brian
Furneaux, Richard Hubert
Kelly, Peter Michael
Schramm, Vern L.
Tyler, Peter Charles
Woolhouse, Anthony David
Gulab, Shivali, Ashwin
Abstract
The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
The use of compounds for promoting the healing of wounds, having the formula 1: where R is a straight or branched chain C1-C30 alkyl which may be substituted by one or more hydroxyl groups or halogen atoms, and may contain one or more epoxy groups. The wounds treatable include chronic wounds, such as cuts, scratches, abrasions, oral ulcers, stomach ulcers, ulcers from cancer therapy, diabetic foot ulcers, venous stasis ulcers, pressure ulcers, and burns, as well as wounds that result from ophthalmic surgery, cosmetic surgery, general surgery, treatment for keloids and hypertrophic scars (anti-scarring treatments).
A process for obtaining lipids containing highly unsaturated fatty acids from plant or animal material, including contacting the material with liquid dimethyl ether to give a dimethyl ether solution containing lipids and a residue of plant or animal material, separating the solution from the residue of plant or animal material, and recovering lipids from the solution.
An imaging system (100) for generating a three-dimensional image of a body part of a patient (102). The imaging system (100) comprises a sensor head (101) that is moved relative to the patient (102) by a robot (103) to conduct a scan of the body part. The sensor head (101) is displaced from the patient (102) and comprises a three-dimensional profiler that is arranged to obtain surface profile information and a radar device that is arranged to obtain radiation information. The imaging system (100) has a control system that is arranged to operate the three-dimensional profiler and radar device. The control system also receives and processes the radiation information and surface profile information to generate a three-dimensional image of the body part that has multiple image points by synthetically focusing the radiation information.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventor
Furneaux, Richard Hubert
Tyler, Peter Charles
Evans, Gary Brian
Schramm, Vern L.
Kim, Kami
Fröhlich, Richard
Abstract
This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.
C07H 19/23 - Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
C07H 5/10 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium to sulfur
C07H 15/14 - Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
30.
METHODS OF TREATING DISEASES USING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventor
Furneaux, Richard Hubert
Tyler, Peter Charles
Evans, Gary Brian
Schramm, Vern L.
Abstract
The invention relates to treating a disease or condition in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase (MTAP) and/or 5'-methylthioadenosine nucleosidase (MTAN). The invention particularly relates to the co-administration of 5'-methylthioadenosine (MTA), or a prodrug of MTA, with one or more MTAP/MTAN inhibitors. Included among the diseases treatable are prostate cancer and head and neck cancer.
A process for fractionating the constituents of a solution obtained by extracting plant or animal material with an aqueous-organic solvent where the aqueous-organic solvent is a mixture of water and a water-miscible organic solvent, generally including the steps of contacting the solution with a near-critical fluid to produce a raffinate phase containing high polarity constituents and water, and a near-critical fluid phase containing low to medium polarity constituents, separating the near-critical fluid phase from the raffinate phase, and recovering the low to medium polarity constituents from the near-critical fluid phase and the high polarity constituents from the raffinate phase.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
ISIS INNOVATION LIMITED (United Kingdom)
Inventor
Furneaux, Richard Hubert
Tyler, Peter Charles
Mee, Simon Peter Harold
Evans, Gary Brian
Schramm, Vern L.
Fleet, George
Abstract
The invention relates to compounds of the formula (I), which are L-enantiomeric forms of nucleoside analogues, and to pharmaceutical compositions containing the compounds, methods of treating certain diseases, including cancer, bacterial infection, parasitic infection, and T-cell mediated diseases, using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds.
C07D 207/04 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07H 5/04 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventor
Furneaux, Richard Hubert
Tyler, Peter Charles
Evans, Gary Brian
Schramm, Vern L.
Clinch, Keith
Abstract
The invention relates to compounds of the formula (I), which are L-enantiomeric forms of nucleoside analogues, and to pharmaceutical compositions containing the compounds, methods of treating certain diseases, including cancer, bacterial infection, parasitic infection, and T-cell mediated diseases, using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds.
C07D 207/04 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07H 5/04 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
34.
FUNCTIONALISED CARBON NANOTUBES AND METHODS OF PREPARATION
The preparation of dithioester functionalised carbon nanotubes (DTE-CNTs) is described. The DTE-CNTs are prepared by reacting suitably functionalised carbon nanotubes with a modified Grignard reagent. The DTE-CNTs are particularly useful as chain transfer agents in reversible addition fragmentation chain transfer (RAFT) polymerisation reactions, and polymer composites prepared using the DTE-CNTs are also described.
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
A hand-held mobile 3D scanner (10) for scanning a scene. The scanner (10) comprises a range sensor (11) that is arranged to sense the location of surface points in the scene relative to the scanner (10) and generate representative location information, a texture sensor (12) that is arranged to sense the texture of each surface point in the scan of the scene and generate representative texture information, and a position and orientation sensor (13) that is arranged to sense the position and orientation of the scanner (10) during the scan of the scene and generate representative position and orientation information. A control system (14) is also provided that is arranged to receive the information from each of the sensors and generate data representing the scan of the scene.
A hand orthosis for assisting gripping by persons with a disability affecting hand function, comprises a thumb part, a hand part which fits around a user’s hand between the thumb and knuckles, a forearm part which fits to a user’s forearm above the hand. The orthosis includes a flexible connecting element connected at one end to the thumb part and which is movably coupled to the hand part and connected at another end to the forearm part such that when the orthosis is fitted to a user, extension of the user’s wrist draws the user’s thumb towards the user’s index finger to form a grip. A powered embodiment of the orthosis is also disclosed.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61F 2/42 - Joints for wrists or anklesJoints for hands, e.g. fingersJoints for feet, e.g. toes
37.
INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
INDUSTRIAL RESEARCH LIMITED (New Zealand)
Inventor
Evans, Gary, Brian
Furneaux, Richard, Hubert
Schramm, Vern, L.
Tyler, Peter, Charles
Mee, Simon, Peter, Harold
Zubkova, Olga, Vladimirovna
Abstract
The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
C07D 473/30 - Oxygen atom attached in position 6, e.g. hypoxanthine
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
A pressure wave generator (40) for driving one or more cryogenic refrigerator systems. The pressure wave generator (40) comprises a housing with one or more inlet/outlet ports (57,58) through which generated pressure waves of gas may pass through to drive a cryogenic refrigerator system or systems connected to the inlet/outlet ports (57,58). The pressure waves are generated by at least one pair of opposed diaphragms (41,42) located in the housing that are moveable in a reciprocating motion within the housing to create pressure waves in gas spaces (55,56) associated with each diaphragm (41,42). The gas spaces (55,56) each having associated inlet/outlet ports (57,58) through which the pressure waves may pass. An operable drive system is also provided to move the pair of diaphragms (41,42) in a reciprocating motion.
F25B 9/00 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point
F25B 9/14 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point characterised by the cycle used, e.g. Stirling cycle
patents